Immeuble Le Sunway
259-261 Avenue Jean JaurEs
Lyon 69007
France
33 4 37 37 20 10
https://www.poxelpharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 15
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D. | Co-Founder, CEO & Director | 412,64k | S.O. | S.O. |
Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D. | Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing Operations | S.O. | S.O. | S.O. |
Dr. Pascale Fouqueray-Grellier M.D., Ph.D. | Co-Founder and Executive VP of Clinical Development & Regulatory Affairs | S.O. | S.O. | S.O. |
Dr. Sophie Hallakou-Bozec Ph.D. | Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication | S.O. | S.O. | S.O. |
Arthur Rouille | Investor Relations Officer | S.O. | S.O. | S.O. |
Mr. Quentin Durand | Executive VP, Chief Legal Officer & Head of Corporate Social Responsibility | S.O. | S.O. | S.O. |
Ms. Sylvie Bertrand | Vice President of Human Resources | S.O. | S.O. | S.O. |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
L’ISS Governance QualityScore de Poxel S.A. en date du 1 avril 2024 est 10. Les scores principaux sont Audit : 5; Société : 9; Droits des actionnaires : 4; Compensation : 10.